medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-3-7-14medsovet-2446Research ArticleЗАБОЛЕВАНИЯ ПИЩЕВОДА И ЖЕЛУДКАESOPHAGEAL AND GASTRIC DISEASESФундаментальные основы кислотопродукции в желудкеBasics of gastric acid secretionМаевИ. В.MaevI. V.

акад. РАН, д.м.н., профессор

MD, Prof.

АндреевД. Н.AndreevD. N.

к.м.н.

PhD in medicine

ЗаборовскийА. В.ZaborovskyA. V.

к.м.н.

PhD in medicine

Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава РоссииРоссияYevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of RussiaRussian Federation20181904201803714Copyright © Маев И.В., Андреев Д.Н., Заборовский А.В., 20182018Маев И.В., Андреев Д.Н., Заборовский А.В.Maev I.V., Andreev D.N., Zaborovsky A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2446

В статье проведена систематизация современных литературных данных о фундаментальных основах кислотопродукции в желудке. Описаны ионные транспортные системы париетальной клетки, задействованные в синтезе соляной кислоты. Рассмотрена молекулярная структура Н+, К+-АТФазы (протонной помпы). Охарактеризованы различные пути регуляции желудочной кислотопродукции (нейральная, гормональная и паракринная) и процессы внутриклеточной сигнальной трансдукции париетальной клетки.

The article provides a systematic review of modern literary data on the basics of gastric acid secretion. It describes the ionic transport systems of the parietal cell involved in the hydrochloric acid synthesis. The molecular structure of H +, K + -ATPhase (proton pump) is discussed. The article characterizes various ways of regulation of gastric acid secretion (neural, hormonal and paracrine) and intracellular signal transduction processes of a parietal cell.

соляная кислотакислотопродукцияантисекреторная терапиякислотозависимые заболеванияингибиторы протонной помпыhydrochloric acidacid secretionantisecretory therapyacid-dependent diseasesproton pump inhibitorsReferencesGuyton and Hall: Textbook of Medical Physiology. Thirteenth edition. Elsevier, 2016.Guyton and Hall: Textbook of Medical Physiology. Thirteenth edition. Elsevier, 2016.Schubert ML, Kaunitz JD. Gastric Secretion. In.: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Edited by Mark Feldman, Law rence S Friedman, Laurence J Brandt. 10th ed. 2015.Schubert ML, Kaunitz JD. Gastric Secretion. In.: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Edited by Mark Feldman, Law rence S Friedman, Laurence J Brandt. 10th ed. 2015.Маев И.В., Самсонов А.А., Андреев Д.Н. Болезни желудка. М.: ГЭОТАР-Медиа, 2015.Maev IV, Samsonov AA, Andreev DN. Stomach diseases. Moscow: GEOTAR-Media, 2015.Руководство по внутренней медицине. Под ред. Г.П. Арутюнова, А.И. Мартынова, А.А. Спасского. М., 2015.Guide to Internal Medicine. Edited by Arutyunova GP, Martynova AI, Spassky AA. M., 2015.Netter’s Gastroenterology, 2nd Edition. Saunders. 2010.Netter’s Gastroenterology, 2nd Edition. Saunders. 2010.Schubert ML. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Curr Opin Gastroenterol, 2017, 33(6): 430-438.Schubert ML. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Curr Opin Gastroenterol, 2017, 33(6): 430-438.Naik SR, Bajaj SC, Goyal RK et al. Parietal cell mass in healthy human stomach. Gastroenterology, 1971, 61: 682-685.Naik SR, Bajaj SC, Goyal RK et al. Parietal cell mass in healthy human stomach. Gastroenterology, 1971, 61: 682-685.Feldman, M. American Journal of Gastroentero-logy lecture: Gastric acid secretion: Still relevant? Am J Gastroenterol, 2013, 108: 347–352.Feldman, M. American Journal of Gastroentero-logy lecture: Gastric acid secretion: Still relevant? Am J Gastroenterol, 2013, 108: 347–352.Андреев Д.Н., Дичева Д.Т., Лебедева Е.Г., Парцваниа-Виноградова Е.В. Фармакологические основы применения ингибиторов протонной помпы. Фарматека, 2014, 14: 62-9Andreev DN, Dicheva DT, Lebedeva EG, Partzvania-Vinogradova EV. Pharmacological principles for the use of proton pump inhibitors. Farmateka, 2014, 14: 62-9Ивашкин В.Т., Лопина О.Д. Клеточные механизмы секреции соляной кислоты и ингибиторы протонного насоса. В кн.: Профилактика и лечение хронических заболеваний верхних отделов желудочно-кишечного тракта. Под ред. акад. РАМН В.Т. Ивашкина. 2-е изд., перераб. и доп. М.: МЕДпресс-информ, 2013Ivashkin VT, Lopina OD. Cellular mechanisms of hydrochloric acid secretion and proton pump inhibitors. In the book: Prevention and treatment of chronic upper gastrointestinal tract diseases. Edited by Acad. of RAMS Ivashkin VT. Revised and additional 2nd ed. М .: MEDPRESS-INFORM, 2013Spicer Z, Miller ML, Andringa A et al. Stomachs of mice lacking the gastric H,K-ATPase α-subunit have achlorhydria, abnormal parietal cells, and ciliated metaplasia. J Biol Chem, 2000, 275: 21555–21565.Spicer Z, Miller ML, Andringa A et al. Stomachs of mice lacking the gastric H,K-ATPase α-subunit have achlorhydria, abnormal parietal cells, and ciliated metaplasia. J Biol Chem, 2000, 275: 21555–21565.Исаков В.А. Ингибиторы протонного насоса: их свойства и применение в гастроэнтеро логии. М.: Академкнига, 2001Isakov VA. Proton pump inhibitors: properties and administration in gas-troenterology. Moscow: Akademkniga, 2001.Asano S, Kawada H, Kimura T et al. The roles of carbohydrate chains of the β-subunit on the functional expression of gastric H+,K+-ATPase. J Biol Chem, 2000, 275: 8324–8330.Asano S, Kawada H, Kimura T et al. The roles of carbohydrate chains of the β-subunit on the functional expression of gastric H+,K+-ATPase. J Biol Chem, 2000, 275: 8324–8330.Heitzmann, D, Warth, R. No potassium, no acid: K+ channels and gastric acid secretion. Physiology, 2007, 22: 335–341.Heitzmann, D, Warth, R. No potassium, no acid: K+ channels and gastric acid secretion. Physiology, 2007, 22: 335–341.Forte JG, Ly B, Rong QF et al. State of actin in gastric parietal cells. Am J Physiol Cell Physiol, 1998, 274: 97–104.Forte JG, Ly B, Rong QF et al. State of actin in gastric parietal cells. Am J Physiol Cell Physiol, 1998, 274: 97–104.Karvar S, Yao X, Duman JG et al. Intracellular distribution and functional importance of vesicle-associated membrane protein 2 in gastric parietal cells. Gastroenterology, 2002, 123: 281–290.Karvar S, Yao X, Duman JG et al. Intracellular distribution and functional importance of vesicle-associated membrane protein 2 in gastric parietal cells. Gastroenterology, 2002, 123: 281–290.Suda J, Zhu L, Okamoto CT et al. Rab27b local-izes to the tubulovesicle membranes of gastric parietal cells and regulates acid secretion. Gastroenterology, 2011, 140: 868–878.Suda J, Zhu L, Okamoto CT et al. Rab27b local-izes to the tubulovesicle membranes of gastric parietal cells and regulates acid secretion. Gastroenterology, 2011, 140: 868–878.Ding X, Deng H, Wang D et al. Phospho-regulated ACAP4-Ezrin interaction is essential for histamine-stimulated parietal cell secretion. J Biol Chem, 2010, 285: 18769–18780.Ding X, Deng H, Wang D et al. Phospho-regulated ACAP4-Ezrin interaction is essential for histamine-stimulated parietal cell secretion. J Biol Chem, 2010, 285: 18769–18780.Schubert ML. Gastric acid secretion. Curr Opin Gastroenterol, 2016, 32(6): 452-460.Schubert ML. Gastric acid secretion. Curr Opin Gastroenterol, 2016, 32(6): 452-460.Chu S, Schubert ML. Gastric secretion. Curr Opin Gastroenterol, 2012, 28: 587-93.Chu S, Schubert ML. Gastric secretion. Curr Opin Gastroenterol, 2012, 28: 587-93.He W, Liu W, Chew CS et al. Acid secretion-associated translocation of KCNJ15 in gastric parietal cells. Am J Physiol Gastrointest Liver Physiol, 2011, 301: 591–600.He W, Liu W, Chew CS et al. Acid secretion-associated translocation of KCNJ15 in gastric parietal cells. Am J Physiol Gastrointest Liver Physiol, 2011, 301: 591–600.Song P, Groos S, Riederer B et al. Kir4.1 channel expression is essential for parietal cell control of acid secretion. J Biol Chem, 2011, 286: 14120–14128.Song P, Groos S, Riederer B et al. Kir4.1 channel expression is essential for parietal cell control of acid secretion. J Biol Chem, 2011, 286: 14120–14128.Kopic S, Murek M, Geibel JP. Revisiting the parietal cell. Am J Physiol Cell Physiol, 2010, 298: C1–C10.Kopic S, Murek M, Geibel JP. Revisiting the parietal cell. Am J Physiol Cell Physiol, 2010, 298: C1–C10.Kosiek O, Busque SM, Foller M et al. SLC26A7 Can function as a chlorideloading mechanism in parietal cells. Pflugers Arch Eur J Physiol, 2007, 454: 989–998.Kosiek O, Busque SM, Foller M et al. SLC26A7 Can function as a chlorideloading mechanism in parietal cells. Pflugers Arch Eur J Physiol, 2007, 454: 989–998.McDaniel N, Pace AJ, Spiegel S et al. Role of Na-K-2Cl cotransporter-1 in gastric secretion of nonacidic fluid and pepsinogen. Am J Physiol Gastrointest Liver Physiol, 2005, 289: G550–G560.McDaniel N, Pace AJ, Spiegel S et al. Role of Na-K-2Cl cotransporter-1 in gastric secretion of nonacidic fluid and pepsinogen. Am J Physiol Gastrointest Liver Physiol, 2005, 289: G550–G560.Rotte A, Pasham V, Mack AF et al. Ca2+ activated K+ channel Kca3.1 as a determinant of gastric acid secretion. Cell Physiol Biochem, 2011, 27: 597–604.Rotte A, Pasham V, Mack AF et al. Ca2+ activated K+ channel Kca3.1 as a determinant of gastric acid secretion. Cell Physiol Biochem, 2011, 27: 597–604.Fujii T, Fujita K, Takeguchi N et al. Function of K+-Cl−-cotransporters in the acid secretory mechanism of gastric parietal cells. Biol Pharm Bull, 2011, 34: 810–812.Fujii T, Fujita K, Takeguchi N et al. Function of K+-Cl−-cotransporters in the acid secretory mechanism of gastric parietal cells. Biol Pharm Bull, 2011, 34: 810–812.Yao X., Forte J.G. Cell biology of acid secretion by the parietal cell. Annu Rev Physiol, 2003, 65: 103-131.Yao X., Forte J.G. Cell biology of acid secretion by the parietal cell. Annu Rev Physiol, 2003, 65: 103-131.Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology, 2008 Jun, 134(7): 1842-60.Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology, 2008 Jun, 134(7): 1842-60.Zhou R, Cao X, Watson C et al. Characterization of protein kinase A-mediated phosphorylation of ezrin in gastric parietal cell activation. J Biol Chem, 2003, 278(37): 35651-9.Zhou R, Cao X, Watson C et al. Characterization of protein kinase A-mediated phosphorylation of ezrin in gastric parietal cell activation. J Biol Chem, 2003, 278(37): 35651-9.Vuyyuru, L, Harrington, L, Arimura, A, Schubert, ML. Reciprocal inhibitory paracrine pathways link histamine and somatostatin secretion in the fundus of the stomach. Am J Physiol Gastrointest Liver Physiol, 1997, 273: G106–G111.Vuyyuru, L, Harrington, L, Arimura, A, Schubert, ML. Reciprocal inhibitory paracrine pathways link histamine and somatostatin secretion in the fundus of the stomach. Am J Physiol Gastrointest Liver Physiol, 1997, 273: G106–G111.Кучерявый Ю.А., Андреев Д.Н. Перспективы лечения больных с кислотозависимыми заболеваниями. Клин. перспективы гастроэнтерол., гепатол., 2014, 2: 15-24Kucheryavy YuA, Andreev DN. Perspectives of treatment of patients with acid-dependent diseases. Klin. per-spektivy gastroenterol., gepatol., 2014, 2: 15-24Lassen AT. Acid-related disorders and use of antisecretory medication. Dan Med Bull, 2007, 54(1): 18-30.Lassen AT. Acid-related disorders and use of antisecretory medication. Dan Med Bull, 2007, 54(1): 18-30.Маев И.В., Андреев Д.Н., Кочетов С.А., Дичева Д.Т. Фармакологические и клинические основы применения ингибиторов протонной помпы. В сб.: Актуальные проблемы гастроэнтерологии. Москва, 28 ноября 2012: 38-45Maev IV, Andreev DN, Kochetov SA, Dicheva DT. Pharmacological and clinical grounds for application of proton pump inhibitors. In collected works: Current gastroenterology problems. Moscow, November 28, 2012: 38-45.Федеральное руководство по использованию лекарственных средств (формулярная система). Выпуск ХVIII. М.: Видокс, 2017.Federal guidelines for proscribing drugs (for-mulary system). 18th Issue. M .: Vidoks, 2017.Андреев Д.Н., Кучерявый Ю.А. Перспективы лечения гастроэзофагеальной рефлюксной болезни. Гастроэнтерология. Приложение к журналу Consilium Medicum, 2013, 2: 9-14.Andreev DN, Kucheryavyy YuA. Prospects for the treatment of gastroesophageal reflux disease. Gastroenterologiya. Appendix to the Journal Consilium Medicum, 2013, 2: 9-14.Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang and Dale’s Pharmacology. Elsevier Churchill Livingstone. 2012.Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang and Dale’s Pharmacology. Elsevier Churchill Livingstone. 2012.Заборовский А.В., Маев И.В., Андреев Д.Н., Тарарина Л.А. Плейотропные эффекты рабепразола и их роль в лечении пациентов с кислотозависимыми заболеваниями. Росc. журн. гастроэнтерологии, гепатологии, колопроктологии, 2017, 27(3): 18-26Zaborovskiy AV, Maev IV, Andreev DN, Tararina LA. Pleiotropic effects of rabeprazole and their role in the treatment of patients with acid-dependent diseases. Rosciyskiy Zhurnal Gastroenterologii, Gepatologii, Koloproktologii, 2017, 27 (3): 18-26.Осипенко М.Ф., Лопина О.Д., Эстулин Д.Г. Плейотропные эффекты рабепразола. РМЖ, 2014, 20: 1448-1470.Osipenko MF, Lopina OD, Estulin DG. Pleiotropic effects of rabeprazole. RMJ, 2014, 20: 1448-1470.Katzung BG, Masters SB, Trevor AJ. Basic & Clinical Pharmacology, 11e. McGraw-Hill Medical. 2009.Katzung BG, Masters SB, Trevor AJ. Basic & Clinical Pharmacology, 11e. McGraw-Hill Medical. 2009.Kromer W, Krüger U, Huber R, Hartmann M, Steinijans VW. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology, 1998, 56(2): 57-70.Kromer W, Krüger U, Huber R, Hartmann M, Steinijans VW. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology, 1998, 56(2): 57-70.Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extra-cytoplasmic thiol reagents. J Biol Chem, 1997, 272(36): 22438-46.Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extra-cytoplasmic thiol reagents. J Biol Chem, 1997, 272(36): 22438-46.Pantoflickova D, Dorta G, Jornod P, Ravie M., Blum A. Identification of the characteristics influencing the degree of antisecretory activity of PPIs [abstract]. Gastroenterology, 2000, 118: A5895.Pantoflickova D, Dorta G, Jornod P, Ravie M., Blum A. Identification of the characteristics influencing the degree of antisecretory activity of PPIs [abstract]. Gastroenterology, 2000, 118: A5895.Tejura B, Boyce M, Warrington S. Rabeprazole is more potent than esomeprazole in control of gastric pH in healthy volunteers [abstract]. Ninth United European Gastroenterology Week Meeting, Amsterdam, The Netherlands. October 2001.Tejura B, Boyce M, Warrington S. Rabeprazole is more potent than esomeprazole in control of gastric pH in healthy volunteers [abstract]. Ninth United European Gastroenterology Week Meeting, Amsterdam, The Netherlands. October 2001.Barnett JL, Robinson M. Optimizing acid-suppression therapy. Manag Care, 2001, 10(10 Suppl): 17-21.Barnett JL, Robinson M. Optimizing acid-suppression therapy. Manag Care, 2001, 10(10 Suppl): 17-21.Desta ZX, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic poly-morphism. Clin. Pharmacokinet., 2002, 41(12): 913– 958. doi: 10.2165/00003088-200241120-00002.Desta ZX, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic poly-morphism. Clin. Pharmacokinet., 2002, 41(12): 913– 958. doi: 10.2165/00003088-200241120-00002.Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol, 2010, 69(3): 222-30. DOI: 10.1111/j.1365-2125.2009.03578.x.Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol, 2010, 69(3): 222-30. DOI: 10.1111/j.1365-2125.2009.03578.x.Serrano D, Torrado S, Torrado-Santiago S, Gisbert JP. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/-pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab, 2012, 13(9): 1303-12.Serrano D, Torrado S, Torrado-Santiago S, Gisbert JP. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/-pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. Curr Drug Metab, 2012, 13(9): 1303-12.Chaudhry AS, Kochhar R, Kohli KK. Genetic pol-ymorphism of CYP2C19 & therapeutic response to proton pump inhibitors. Indian J. Med. Res., 2008, 127(6): 521–530.Chaudhry AS, Kochhar R, Kohli KK. Genetic pol-ymorphism of CYP2C19 & therapeutic response to proton pump inhibitors. Indian J. Med. Res., 2008, 127(6): 521–530.Маев И.В., Андреев Д.Н. Молекулярно-генетические предикторы резистентности к антихеликобактерной терапии. Терапевтический архив, 2017, 89(8): 5-12Maev IV, Andreev DN. Molecular-genetic predictors of resistance to anti-Helicobacter therapy. Terapevticheskiy arkhiv, 2017, 89 (8): 5-12.Ichikawa H, Sugimoto M, Sugimoto K, Andoh A, Furuta T. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol, 2016, 31(4): 716-26.Ichikawa H, Sugimoto M, Sugimoto K, Andoh A, Furuta T. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol, 2016, 31(4): 716-26.Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol, 2014, 20(43): 16029-36.Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol, 2014, 20(43): 16029-36.Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol, 2006, 101(7): 1467-75.Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol, 2006, 101(7): 1467-75.Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res, 2001, 18(6): 721-7.Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res, 2001, 18(6): 721-7.Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmöller J. Relative potency of proton-pump inhibitors-comparison of effects on intra-gastric pH. Eur J Clin Pharmacol, 2009, 65(1): 19-31.Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmöller J. Relative potency of proton-pump inhibitors-comparison of effects on intra-gastric pH. Eur J Clin Pharmacol, 2009, 65(1): 19-31.Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Sahara S, Ichikawa H, Kagami T, Sugimoto K, Furuta T. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. Eur J Clin Pharmacol, 2014, 70(9): 1073-8.Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Sahara S, Ichikawa H, Kagami T, Sugimoto K, Furuta T. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. Eur J Clin Pharmacol, 2014, 70(9): 1073-8.

The authors declare that there are no conflicts of interest present.